Hotdog is to bun like Afrezza is to
Jul 23, 2018 21:02:05 GMT -5
alethea, sportsrancho, and 4 more like this
Post by joeypotsandpans on Jul 23, 2018 21:02:05 GMT -5
You can have one without the other but just not quite the same 
.....huge difference when I got my Libre after the first couple of months without it, just sayin, common sense folks, time to play ball and step to the plate....top of the 1st inning:
www.startribune.com/abbott-labs-beats-earnings-estimates-hikes-guidance/488504051/
Abbott Labs sees big upside for its FreeStyle Libre glucose monitor
Strong growth for its diabetes unit was key to driving second quarter earnings that exceeded expectations.
By Joe Carlson Star Tribune JULY 18, 2018 — 3:48PM
TEXT SIZE
0
EMAIL
PRINT
MORE
Abbott Laboratories expects that more than 1 million diabetics worldwide will be using its new FreeStyle Libre continuous glucose monitor (CGM) before the year is out, and the company is investing heavily to expand production capacity for the mass-market medical device.
In an earnings call Wednesday to announce better than expected second quarter results, Abbott chief executive Miles White said the Illinois-based health care products company is on track to exceed its goal of at least $90 million in U.S. sales for the Libre in 2018.
The device was approved in the U.S. last fall as the nation's first sensor that can continuously monitor adult blood sugar without requiring a blood sample for calibration.
White said a key part of the device's appeal its "economically accessible" price for patients and insurers. In a market in which other devices for insulin-dependent patients can cost thousands of dollars, the FreeStyle Libre sensor carries a $36 price tag for 10 days' use in the U.S., meaning it costs about $1,300 a year at list prices.
"It's got so much potential," White told the analysts on the call. "A lot of times, whether it is a pharmaceutical or a medical device, they can be expensive in the healthcare system ... because the numbers of patients may not be that great. And yet, there's a lot of diabetics in the world, including me."
Abbott competes with Minnesota's Medtronic for diabetes-device sales, though the two companies have dissimilar offerings. Medtronic is heavily invested in sophisticated insulin pumps, but only recently entered the market for stand-alone CGMs; Abbott has a strong foothold in the burgeoning CGM market, while it is partnering with California's Bigfoot Biomedical to develop next-generation insulin-delivery devices that are still in clinical testing.
The 34 percent quarterly organic growth in Abbott's $470 million diabetes care unit helped offset losses elsewhere in its medical device portfolio, particularly with the heart-rhythm devices that Abbott acquired last year when it bought Minnesota pacemaker maker St. Jude Medical, earnings figures released Wednesday show.
.....huge difference when I got my Libre after the first couple of months without it, just sayin, common sense folks, time to play ball and step to the plate....top of the 1st inning:www.startribune.com/abbott-labs-beats-earnings-estimates-hikes-guidance/488504051/
Abbott Labs sees big upside for its FreeStyle Libre glucose monitor
Strong growth for its diabetes unit was key to driving second quarter earnings that exceeded expectations.
By Joe Carlson Star Tribune JULY 18, 2018 — 3:48PM
TEXT SIZE
0
MORE
Abbott Laboratories expects that more than 1 million diabetics worldwide will be using its new FreeStyle Libre continuous glucose monitor (CGM) before the year is out, and the company is investing heavily to expand production capacity for the mass-market medical device.
In an earnings call Wednesday to announce better than expected second quarter results, Abbott chief executive Miles White said the Illinois-based health care products company is on track to exceed its goal of at least $90 million in U.S. sales for the Libre in 2018.
The device was approved in the U.S. last fall as the nation's first sensor that can continuously monitor adult blood sugar without requiring a blood sample for calibration.
White said a key part of the device's appeal its "economically accessible" price for patients and insurers. In a market in which other devices for insulin-dependent patients can cost thousands of dollars, the FreeStyle Libre sensor carries a $36 price tag for 10 days' use in the U.S., meaning it costs about $1,300 a year at list prices.
"It's got so much potential," White told the analysts on the call. "A lot of times, whether it is a pharmaceutical or a medical device, they can be expensive in the healthcare system ... because the numbers of patients may not be that great. And yet, there's a lot of diabetics in the world, including me."
Abbott competes with Minnesota's Medtronic for diabetes-device sales, though the two companies have dissimilar offerings. Medtronic is heavily invested in sophisticated insulin pumps, but only recently entered the market for stand-alone CGMs; Abbott has a strong foothold in the burgeoning CGM market, while it is partnering with California's Bigfoot Biomedical to develop next-generation insulin-delivery devices that are still in clinical testing.
The 34 percent quarterly organic growth in Abbott's $470 million diabetes care unit helped offset losses elsewhere in its medical device portfolio, particularly with the heart-rhythm devices that Abbott acquired last year when it bought Minnesota pacemaker maker St. Jude Medical, earnings figures released Wednesday show.
